CROSSTEC (03893) completes the placement of 31.104 million shares.
YiWei Group (03893) announced that all conditions stipulated in the subscription agreement have been met, and the subscription has been completed on 20...
CROSSTEC (03893) announced that all conditions stated in the placement agreement have been met, and the placement was completed on February 28, 2025. A total of 31.104 million shares (equivalent to approximately 16.67% of the enlarged issued share capital of the company after completion) were successfully placed to six subscribers at a placement price of HK$0.20 per share in accordance with the terms of the placement agreement.
Related Articles
CINDA INTL HLDG(00111) purchases bonds with a principal amount totaling 30 million RMB.
NIRAKU (01245) entered into a trust beneficiary transfer agreement with SMFL MIRAI Partners Company.
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injectable drug SHR-1501 included in the list of breakthrough therapies under consideration.
CINDA INTL HLDG(00111) purchases bonds with a principal amount totaling 30 million RMB.
NIRAKU (01245) entered into a trust beneficiary transfer agreement with SMFL MIRAI Partners Company.
Jiangsu Hengrui Pharmaceuticals(600276.SH): Injectable drug SHR-1501 included in the list of breakthrough therapies under consideration.
